SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID Phase 3 trials will be presented at the following medical meetings:
Digestive Disease Week (DDW), McCormick Place, Chicago, IL May 7-10, 2011 | ||
Poster Presentation Information: | ||
Title: | Risk of Recurrence and Time to Recurrence Following Treatment of Clostridium | |
difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin | ||
vs. Vancomycin | ||
Presenter: | Kathleen M. Mullane, D.O. | |
Date: | Saturday, May 7, 2011 | |
Time: | 12:00 p.m. to 2:00 p.m. Central Time | |
Location: | Poster Session Hall A (MCP) | |
Session: | Intestinal Disorders: Prebiotics, Probiotics and Pathogens | |
Program #: | Sa1981 | |
Poster Presentation Information: | ||
Title: | High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 in | |
Patients with C. difficile infection: Combined Results of Two Phase 3 Trials | ||
Presenter: | Pamela S. Sears, Ph.D. | |
Date: | Monday, May 9, 2011 | |
Time: | 12:00 p.m. to 2:00 p.m. Central Time | |
Location: | Poster Session Hall A (MCP) | |
Session: | Randomized Controlled Clinical Trials | |
Program #: | Mo1160 | |
European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milano Convention Center, Milan, Italy May 7-10, 2011 | ||
Oral Presentation Information: | ||
Title: | Immunosuppression and the Risk of Death, Cure Rates and Disease Recurrence | |
Among Patients with Clostridium difficile Infection | ||
Presenter: | Yoav Golan, M.D., M.S. | |
Date: | Tuesday, May 10, 2011 | |
Time: | 10:36 a.m. to 10:48 a.m. Central European Time | |
Location: | Lecture Hall Brown 1 | |
Oral Session: | C. difficile News | |
Presentation #: | O504 | |
Poster Presentation Information: | ||
Title: | Clostridium difficile Recurrence, Alcohol Consumption, and the Effect of | |
Fidaxomicin vs. Vancomycin | ||
Presenter: | Yoav Golan, M.D., M.S. | |
Date: | Tuesday, May 10, 2011 | |
Time: | 12:30 p.m. to 1:30 p.m. Central European Time | |
Location: | Poster Area Hall 5 | |
Poster Topic 99: | Clostridium difficile | |
Poster ID#: | P1968 | |
2011 Annual Scientific Meeting of the American Geriatrics Society (AGS), The Gaylord National Hotel, National Harbor, Maryland May 11-14, 2011 | ||
Poster Presentation Information: | ||
Title: | Effect of Advancing Age on Outcomes of Therapy for Clostridium difficile Infection | |
Presenter: | Thomas J. Louie, M.D. | |
Date: | Thursday, May 12, 2011 | |
Time: | 4:30 p.m. to 6:00 p.m. Eastern Time | |
Session: | Presidential Poster Session B | |
Location: | Exhibit Hall | |
Poster ID#: | B126 | |
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID (fidaxomicin) and Pruvel (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company’s request for six-month Priority Review of Optimer’s NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.
